Synta Pharmaceuticals, Inc. (SNTA) Reports Q3 Loss of $0.30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts SNTA Hot Sheet
Price: $0.34 --0%
Financial Fact:
Total operating expenses: 14.09M
Today's EPS Names:
SMXT, NRIX, VFS, More
Financial Fact:
Total operating expenses: 14.09M
Today's EPS Names:
SMXT, NRIX, VFS, More
Join SI Premium – FREE
Synta Pharmaceuticals, Inc. (NASDAQ: SNTA) reported Q3 EPS of ($0.30), $0.01 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.71 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nurix Therapeutics, Inc. (NRIX) Reports Q3 EPS of $4.73
- Delta Air Lines Q3 earnings preview: stronger print expected, fuel impact in focus
- Cryo-Cell International, Inc. (CCEL) Tops Q3 EPS by 13c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
